After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...